Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Orphan Status
Biotech
Ovid's fragile X drug shows promise in phase 2
Ovid Therapeuctics’ lead program improved behavioral symptoms, as well as anxiety and mood, in a small phase 2 study in fragile X syndrome.
Amirah Al Idrus
May 7, 2020 10:35am
FDA still not happy with Kamada inhaled AAT drug
Apr 23, 2018 9:45am
Barclays loses patience with Gilead, tells it to change up its strategy
Mar 10, 2017 4:16am
Fidelity backs rare disease startup with $48M to get pivotal data
Oct 3, 2016 9:43am